

# Supporting Information

Machida *et al.* 10.1073/pnas.0807390106

## SI Methods

**Cells.** Huh7 cells were plated at  $3 \times 10^5$  or  $2 \times 10^6$  cells per 6-well or 10-cm dish and transfected with expression plasmids and a reporter construct.

**Histology and Immunohistochemistry.** Mouse livers from different genetic and treatment groups were fixed in neutral-buffered 4% paraformaldehyde at 4°C and processed for paraffin embedding. Five-micrometer sections were stained with hematoxylin and eosin. Immunohistochemistry staining of cryosections or paraffin sections was performed by using antibodies against TLR4 (HTA125; eBioscience), phospho-JNK (Santa Cruz Biotechnology), phospho-I $\kappa$ B (Cell Signaling Technology), TNF- $\alpha$  (RM9011; CALTAG), or Nanog (Abcam) based on the standard protocol with mounting media, including DAPI for nuclei counterstaining (Vector Laboratories), according to the manufacturer's recommendations.

**Human Subjects.** Necropsy liver tissues from patients with HCV infection with or without a history of alcoholism were obtained as cryopreserved samples according to the approved Institutional Review Board protocol. The samples were carefully screened for coinfection with other hepatitis virus or HIV as determined by serological tests, drug addiction, and comorbidities other than alcoholism as tested by clinical laboratory tests, and such samples were excluded from the study. Necropsy liver specimens from 8 HCV infected patients were examined for immunohistochemistry and immunoblot analysis. Four patients had a history of having more than 4 drinks per day for more than 15 years. The other 4 patients reportedly consumed alcohol only occasionally in a very moderate amount. They were all male with ages of 27–59 years, but no information on smoking was available. Histologically, they all had a varying degree of steatosis (microvesicular and macrovesicular) and inflammation, and these changes were more pronounced in alcohol-consuming HCV patients. Frozen necropsy liver tissues from patients with stroke but without apparent liver pathology were also obtained for immunoblotting.

**Gene Array Analysis of Liver Tumors.** For gene profiling, the Affymetrix mouse gene chip (GeneChip Mouse Genome 430A 2.0) was used, and analysis was performed in the Genome Core Facility at Los Angeles Children's Hospital. We performed microdissection to collect hepatocytes from NS5A Tg mice fed alcohol and wild-type (WT) mice fed alcohol for 12 months (14 months old). We prepared serial cryosections from 5 mice (3 males and 2 females) from each group, stained them with H&E, and collected hepatocytes from non-tumor-bearing areas using laser-capture microscopy as described previously (1–3). A minimum of 100–200 cells were collected from each of 5 animals in both groups, and RNA individually extracted was pooled for each group for the analysis (1, 2, 4–6). Three different batches of RNA from different areas were prepared and used for microarray analysis. For gene profiling analysis, the Affymetrix mouse gene chip (GeneChip Mouse Genome 430A 2.0) was used in the Genome Core Facility at Los Angeles Children's Hospital. Data analysis was performed by using Partek Pro 5.1 (Partek Inc.). The normalization of the array data and statistical analysis were performed as described previously (7–9).

**Plasmids, Lentivirus, and Retrovirus Vectors.** The NS5A expression plasmid was constructed by inserting HCV NS5A cDNA behind the CMV promoter in pCDNA3.1 (Invitrogen). Lentivirus vectors were prepared by standard procedures in HEK293T cells. Three plasmids, packaging vector pPAX2 (Addgene), ecotropic envelope gene expression vector pMDV (Addgene), and the cassettes of shRNA were transfected in HEK293T cells by lipid-based transfection reagent FuGene6 (Roche). The retroviral expression vectors for shRNA of TLR4 and Nanog were obtained from Open Biosystems. Retrovirus expressing TLR4 was produced in Phoenix cells (10). After 72 hours of transfection, the virus supernatants were harvested and mixed with polybrene (4  $\mu$ g/mL) and used to infect Huh7 cells. More detailed states of the patients are depicted in *SI Methods*.


**Statistical Analysis.** Statistical analysis of the data in [Tables S1–S3](#) was performed by the  $\chi^2$  test or Student's *t* test. Values of *P* < 0.05 were considered to be statistically significant.

## SI Discussion

One potential concern about the NS5A Tg used for the present study is that the protein may be overexpressed beyond the physiological range in chronic HCV infection, rendering artificial effects in the model. However, our immunoblot analysis comparing NS5A expression in livers of HCV patients and NS5A mice reveals NS5A expression in patient samples at the level approximating one third of the mouse Tg expression. Therefore, the NS5A expression in our model does not appear to be too excessive or unphysiological. In natural HCV infection, other viral proteins are also expressed and they may have interactive effects. Obviously, our animal model does not reproduce this environment as it is intended to specifically test the effects of the protein NS5A. In fact, because of this approach, we were able to reveal the novel roles of TLR4 and Nanog in their oncogenic potential in the context of the synergism specifically mediated by NS5A and alcohol. The roles of JNK and IKK in liver oncogenesis are important questions. AP-1 is activated in both HCC and chronic hepatitis (11). In vitro studies using liver-derived cell lines demonstrate rapid activation of AP-1 by HBV or HCV proteins (12). Our study also shows activation of JNK in alcohol-fed NS5A Tg mice in concurrence with the increased risk of liver tumors ([Fig. S4](#)). JNK-AP1 activation may induce compensatory cell proliferation via induction of growth factors such as IL-6, TNF- $\alpha$ , and HGF. This regenerative proliferation is considered as a predisposing condition for permanent oncogenic mutations in initiated hepatocytes for transmission to daughter cells (13–16). NF- $\kappa$ B activation protects the cells by induction of anti-apoptotic and anti-oxidant genes such as superoxide dismutase (SOD). Indeed, hepatocyte IKK $\beta$  inhibits liver carcinogenesis via attenuation of oxygen radical formation, and mice deficient in IKK $\beta$  are predisposed to JNK1-mediated oxidant stress and chemically induced liver tumors (13, 15). In our mouse model, NF- $\kappa$ B is activated by TLR4 signaling and this activation correlates with the expression of proinflammatory genes such as TNF- $\alpha$ . This pro-inflammatory response may also augment JNK-mediated hepatocellular damage and transformation. Our study did not address which isoform of JNK (JNK1/2) is responsible for NS5A-TLR4 mediated liver damage and oncogenesis, and this is an obvious question which will need to be addressed in future studies.


1. Marko-Varga G, Berglund M, Malmstrom J, Lindberg H, Fehniger TE (2003) Targeting hepatocytes from liver tissue by laser capture microdissection and proteomics expression profiling. *Electrophoresis* 24:3800–3805.
2. Michel C, et al. Liver gene expression profiles of rats treated with clofibrilic acid: comparison of whole liver and laser capture microdissected liver. (2003) *Am J Pathol* 163:2191–2199.
3. Espina V, Millia J, Wu G, Cowherd S, Liotta LA (2006) Laser capture microdissection. *Methods Mol Biol* 319:213–229.
4. Wulfkuhle JD, et al. (2002) Proteomics of human breast ductal carcinoma in situ. *Cancer Res* 62:6740–6749.
5. Wulfkuhle JD, Liotta LA, Petricoin EF (2003) Proteomic applications for the early detection of cancer. *Nat Rev Cancer* 3:267–275.
6. Espina V, et al. Protein microarrays: Molecular profiling technologies for clinical specimens. (2003) *Proteomics* 3:2091–2100.
7. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. *Proc Natl Acad Sci USA* 100:9440–9445.
8. Sitkiewicz I, Musser JM (2006) Expression microarray and mouse virulence analysis of four conserved two-component gene regulatory systems in group a streptococcus. *Infect Immun* 74:1339–1351.
9. Graham MR, et al. (2005) Group A streptococcus transcriptome dynamics during growth in human blood reveals bacterial adaptive and survival strategies. *Am J Pathol* 166:455–465.
10. Saitoh S, et al. (2004) Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. *Int Immunol* 16:961–969.
11. Liu P, et al. (2002) Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. *J Hepatol* 37:63–71.
12. Kato N, et al. (2000) Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. *Hepatology* 32:405–412.
13. Sakurai T, et al. (2008) Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. *Cancer Cell* 14:156–165.
14. Eferl R, et al. (2003) Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. *Cell* 112:181–192.
15. Sakurai T, Maeda S, Chang L, Karin M (2006) Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. *Proc Natl Acad Sci U S A* 103:10544–10551.
16. Maeda S, Kamata H, Luo JL, Leffert H, Karin M (2005) IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. *Cell* 121:977–990.





**Fig. 52.** NS5A and TLR4 induction in alcoholic HCV patients. (A) NS5A protein expression was assessed by immunoblot analysis in liver protein extracts from stroke patients with normal livers and HCV patients without or with the history of alcoholism compared with NS5A Tg mouse livers. (B) Densitometry results of NS5A proteins normalized by  $\beta$ -actin are shown. HCV patients with or without alcoholism had comparably induced NS5A protein expression at the level approximating one third of the expression observed in NS5A Tg mice. (C–F) Liver sections from healthy livers from stroke patients and hepatitis C patients with or without alcoholism were stained for TLR4, phospho-JNK, and phospho-I $\kappa$ B. Note colocalization signals (merged images) for TLR4 with phospho-JNK or phospho-I $\kappa$ B were increased in nonalcoholic and alcoholic HCV patients. (F) Negative control staining of liver sections from an HCV patient using isotype nonimmune antibody.





**Fig. S4.** Long-term alcohol feeding causes enhanced activation of TLR4 signaling in NS5A Tg mice. (A) Alcohol feeding for 12 months resulted in accentuated TLR4 signaling, as demonstrated by enhanced interaction of TAK1 with TRAF6 and increased expression of phosphor-JNK and phosphor-I $\kappa$ B in the livers of NS5A Tg mice compared with alcohol-fed wild-type (WT) mice or WT and NS5A Tg mice fed a control diet. (B) Accentuated TLR4 signaling in the livers of alcohol-fed NS5A Tg mice was completely prevented by TLR4 deficiency (Tlr4<sup>-/-</sup>NS5A). (C) Liver cyosections from NS5A Tg and WT mice fed alcohol for 12 months were stained for TLR4, TNF- $\alpha$ , phospho-I $\kappa$ B, and phospho-JNK. Note increased colocalization of TLR4 staining with the staining for TNF- $\alpha$ , phospho-I $\kappa$ B, and phospho-JNK in alcohol-fed NS5A Tg mice compared with alcohol-fed WT mice.

**A NS5A + Alcohol vs. Wild type + Alcohol (Microarray)**

Function	Gene name	Fold change
<b>Stem cell</b>	Nanog homeobox (Nanog)	5.1
<b>Cytokine</b>	Interferon alpha 4 (Ifna4)	5.3
<b>Chromatin remodeling</b>	Absent, small, homeotic discs 1 (ASH1); Trithorax group	0.02
<b>Transcription factor</b>	Absent, small, homeotic discs 1 (ASH2); Trithorax group	0.07
	Homeo box D12 (HoxD12) <sup>#</sup>	0.42
	Homeo box C6 (HoxC6) <sup>#</sup>	0.45
	Homeo box C8 (HoxC8)	0.45
	Homeo box A9 (HoxA9)	0.48
	Myomesin M2 (MyoM2)	0.042
	Myomesin Z1 (MyoZ1)	0.13
	Myomesin Z2 (MyoZ2)	0.27
	Myogenic differentiation D1 (MyoD1) <sup>#</sup>	0.42
	Sine oculis-related homeobox 6 homologue (Six6) <sup>#</sup>	0.45
	Early B-cell factor 3 (Ebf3) <sup>#</sup>	0.37
	Paired box gene 6 (Pax6) <sup>#</sup>	0.42
	Inactive X specific transcripts (Xist)	0.41
	Forkhead box L1 (FoxL1) <sup>#</sup>	0.28
	Forkhead box O4 (FoxO4)	0.35
	Forkhead box D3 (FoxD3) <sup>#</sup>	0.44
	IKAROS family zinc finger 4 (Ikzf4)	4.7
<b>Apoptosis</b>	B-cell leukemia/lymphoma 2 related protein A1a (Bcl2a1a)	7.3
	B-cell CLL/lymphoma 11A (zinc finger protein) (Bcl11a)	4.3
<b>Chromosome</b>	Telomerase maintenance 2 (TEL2)	0.0036
	SWI/SNF related matrix associated	0.0034
<b>Metabolism</b>	Metallothionein 2 (Mtf2)	4.0
<b>Membrane</b>	Amyloid beta (A4) precursor protein (App)	9.5
	Serum amyloid A 2 (Saa2)	9.4

<sup>#</sup>: Promoter sequence has Nanog binding region  
<sup>#</sup>: Promoter sequence has SUZ12 binding region

**B NS5A + Alcohol vs. Wild type + Alcohol (Microarray)**

	Fold change		Fold change		
glycosylation dependent cell adhesion molecule 1	Glycam1	125.5	homeo box A9	Hoxa9	0.4865
interlectin 1 (galactofuranose binding) // similar to Interlectin-1Rtn1 // LOC640587	Itln1	33.1	forkhead box N4	Foxn4	0.4760
homeo box D9	Hoxd9	25.2	homeo box C5	Hoxc5	0.4585
IKAROS family zinc finger 4	Ikzf4	18.1	homeo box C6	Hoxc6	0.4572
similar to Iq heavy chain V region 108A precursor // similar 1 LOC100048770		16.7	forkhead box D3	Foxd3	0.4478
peptidylprolyl isomerase (cyclophilin) like 5	Ppi5	15.5	homeo box D12	Hoxd12	0.4228
G protein-coupled receptor 1376	Gpr137b	12.8	myogenic differentiation 1	Myod1	0.4225
immunoglobulin mu binding protein 2	Ighmbp2	11.3	myomesin 1	Myom1	0.4180
kallikrein 1-related peptidase b3	Krk1b3	10.5	early B-cell factor 3	Ebf3	0.3721
somatostatin receptor 3	Sstr3	10.0	transferin receptor	Tfrc	0.3714
amyloid beta (A4) precursor protein	App	9.5	granzyme N	Gzmn	0.3676
serum amyloid A 2	Saa2	9.4	v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog	Kras	0.3650
hyaluronoglucosaminidase 1	Hyal1	8.8	forkhead box O4	Foxo4	0.3557
deoxyribonuclease 1-like 3	Dnase1l3	8.7	interferon regulatory factor 7	Irf7	0.3515
cDNA sequence BC006965	BC006965	8.7	NADPH oxidase 4	Nox4	0.3325
keratin 14	Krt14	8.6	2'-5' oligoadenylate synthetase 1D1/E	Oas1d1/e	0.3192
immunoglobulin heavy chain complex // Immunoglobulin heavy chain // Ighg		8.5	early B-cell factor 2	Ebf2	0.2564
S100 calcium binding protein G	S100g	8.1	G protein-coupled receptor 96	Gpr96	0.2469
twenty homolog 1 (Drosophila)	Tyh1	8.0	Shc1p1	Shc1p1	0.2469
cDNA sequence U46068	U46068	7.6	zinc finger CCHC type containing 3	Zc3h3	0.2495
macrophage 1	Mrc1	7.6	cell cycle exit and neuronal differentiation 1	Genf1	0.2494
granzyme G	Gzmg	7.4	DnaJ (Hsp40) homolog	Dnaj1	0.2487
tripartite motif protein 16	Trim16	7.4	calcium-binding tyrosine(Y)-phosphorylation regulated	Cabyr	0.2474
B-cell leukemia/lymphoma 2 related protein A1a // B-cell leu Bcl2a1a // Bcl2a1b		7.3	RIKEN cDNA 1700120B22 gene	1700120B22Rik	0.2469
ankyrin repeat domain 1 (cardiac muscle)	Ankrd1	7.2	G protein-coupled receptor 98	Gpr98	0.2469
lipocalin 2	Lcn2	7.2	ATPase	Na+/K+ transporting	0.2469
mitogen activated protein kinase 8 interacting protein 1	Mapk8ip1	7.0	gap junction membrane channel protein alpha 5	Gja5	0.2462
involucrin	Ivl	6.9	cholecytokinin A receptor	Cckar	0.2434
centromere protein E	Cenpe	6.8	Wnt inhibitory factor 1	Wif1	0.2422
Immunoglobulin heavy chain 6 (heavy chain of IgM)	Ighm6	6.8	thyroglobulin	Tg	0.2419
testis expressed gene 18	Tex18	6.7	G-protein-coupled receptor 50	Gpr50	0.2419
high-mobility group box 4	Hmgb4	6.6	RIKEN cDNA 23110039E09 gene	23110039E09Rik	0.2413
cysteine-rich secretory protein 2	Crsp2	6.3	leucine zipper protein 1	Luzp1	0.2380
cysteine-rich protein 3	Crip3	6.2	alpha teloprotein	Atpl	0.2378
gonadotropin releasing hormone receptor	Gnrhr	6.0	chemokine (C-X-C motif) ligand 13	Cxcl13	0.2362
mitogen activated protein kinase 10	Mapk10	6.0	sine oculis-related homeobox 6 homologue (Drosophila)	Six6	0.2381
G protein-coupled receptor 44	Gpr44	6.0	preprolactin protein (myelin) 1	Prlp1	0.2321
regenerating islet-derived 3 alpha	Reg3a	5.9	saraline (or cysteine) peptidase inhibitor	diada F	0.2315
mitochondrial ribosomal protein L41	Mpl41	5.9	nuclear transcription factor-Y alpha	NfyA	0.2284
protocadherin beta 10	Pcdh10	5.6	lipocalin 13	Lcn13	0.2280
angiotensin-like 2	Angpt2	5.5	DEAH (Asp-Glu-Ala-His) box polypeptide 9	Dhx9	0.2255
pancreatic lipase-related protein 2	Pnlipr2	5.5	stathmin-like 2	Stmn2	0.2255
in-28 homolog (C. elegans)	Lrn28	5.3	ubiquitin D	Ubd	0.2209
interferon alpha 4	Ifna4	5.3	ribosomal protein L3-like	Rpl3l	0.2203
olfactory receptor 1507	Olf1507	5.2	galactose 4-epimerase	Galc	0.2185
expressed sequence AA522020	AA522020	5.1	proteasome (prosome)	macropain) subunit	0.2181
Nanog homeobox	Nanog	5.1	proteasome (prosome)	311004J09Rik	0.2111
chloride channel calcium activated 3	Cic3a	5.0	RIKEN cDNA 311004J09 gene	subunit VI a	0.2102
phytanoyl-CoA hydroxylase interacting protein-like	Phyhlpl	5.0	cytochrome c oxidase	Coc53	0.2102
zinc finger protein 706	Zfp706	5.0	colicoid domain containing 53	Klfc5	0.2096
retinal pigment epithelium 65	Rpe65	5.0	kinesin family member 5C	Shcbp1	0.2090
expressed sequence A1586015	A1586015	4.9	hypothetical LOC867597	LOC867597	0.2090
bisecting cell adhesion molecule-related	Boc	4.9	proteasome (prosome)	macropain) subunit	0.2072
a disintegrin and metalloproteinase domain 3 (cytostatin)	Adis3	4.9	proteasome (prosome)	Lmo2	0.2051
forkhead box B2	Foxb2	4.7	enraged 1	En1	0.2043
receptor tyrosine kinase-like orphan receptor 1	Ror1	4.7	RIKEN cDNA C330027C09 gene	C330027C09Rik	0.2031
annexin A2	Anxa2	4.7	expressed sequence AH51617	AH51617	0.2018
LIM homeobox protein 9	Lhx9	4.6	similar to MMS1 oncogene	LOC100048871	0.2006
expressed sequence BB001228	BB001228	4.6	doublecortin	Dcx	0.2004
expressed sequence C76554	C76554	4.5	trophoblast glycoprotein	Tpbg	0.1983
acyl-CoA synthetase bubblegum family member 1	Acbg1	4.4	caspase 4	Casp4	0.1979
Neptrophin	Nptn	4.4	teratocarcinoma-derived growth factor // similar to cripto	LOC10004	0.1947
sialic acid binding Ig-like lectin 5	Siglec5	4.4	chloride channel	0.1835	
twenty homolog 1 (Drosophila)	Tyh1	4.3	chemokine (C-X-C motif) ligand 13	Cxcl13	0.1830
syntaxin 152 // syntaxin 1B1	Sxt151 // Sxt1b2	4.3	casein alpha s2-like A	Csn1s2a	0.1823
CD209e antigen	Cd209e	4.3	sex determining region of Chr Y	Sry	0.1712
spermatid perinuclear RNA binding protein	Strbp	4.3	RAD51 associated protein 1	Rad51ap1	0.1668
B-cell CLL/lymphoma 11A (zinc finger protein)	Bcl11a	4.3	ATP-binding cassette	sub-family	0.1630
expressed sequence C77545	C77545	4.3	VATPase	H+ transp	0.1626
histocompatibility 28	H28	4.2	ATPase	H+ transp	0.1621
transmembrane protein 45a	Tmem45a	4.2	proteasome (prosome)	macropain) 26S subunit	0.1500
zona pellucida 3 receptor	Zp3r	4.2	proteasome (prosome)	macropain) subunit	0.1496
Immunoglobulin heavy chain (gamma polypeptide)	Ighg	4.2	interferon-induced protein 44	Ifi44	0.0915
beaded filament structural protein in lens-CP94	Bfsp1	4.1	NADH dehydrogenase (ubiquinone) 1	subcomplex unknown	0.0598
ubiquitin carboxyl-terminal esterase L4	Uch4	4.1	succinate dehydrogenase complex	subunit C	0.0589
Down syndrome cell adhesion molecule-like 1	Dscam1	4.1	DnaJ (Hsp40) homolog	subfamily C	0.0567
inhibitor of DNA binding 4 // similar to Id4	Id4 // LOC1000455	4.1	potassium voltage-gated channel	shaker-related subfamily	0.0496
DAZ interacting protein 1	Dzip1	4.1	potassium channel	subfamily K	0.0495
metallothionein 2	Mtf2	4.0	lectin	galactose	0.0474
cyclin G associated kinase	Gak	4.0	nuclear receptor subfamily 4	group A	0.0083
zinc finger protein 61	Zfp61	4.0	procollagen	type IV	0.0074
			amyloid beta (A4) precursor protein-binding	family A	0.0073
			nuclear factor of activated T-cells	cytoplasm	0.0072
			dynein	axonemal	0.0037
			TEL2	telomere maintenance 2	0.0026
			golgi associated	gamma adaptin ear containing	0.0020
			carbamoyl-phosphate synthetase 2	aspartate 1	0.0019
			glutamate receptor	ionotropic	0.0018
			melanoma antigen	family L	0.0011
			calcium channel	voltage-de	0.0010
			potassium voltage-gated channel	isk-related	0.0000
			tyrosine kinase	non-recep	0.0005
			protein tyrosine phosphatase	receptor type	0.0005
			SAM domain	SH3 domain and nuclear localization signals	0.0004

**Fig. S5.** Differentially regulated genes in the livers of NS5A Tg mice fed alcohol for 12 months. DNA microarray analysis was performed in the livers of NS5A Tg mice and wild-type mice fed alcohol for 12 months as described in *SI Methods*. (A) This list summarizes differentially regulated genes in alcohol-fed NS5A mouse livers for different functional groups. Of note is the 5.1-fold induction of the stem cell marker Nanog. (B) A partial list of genes up-regulated by more than 4-fold or down-regulated by more than 2-fold in the livers of alcohol-fed NS5A Tg mice compared with alcohol-fed wild-type mice.

**Table S1. Liver histological grading of NS5A Tg mice with or without TLR deficiency after 4-week alcohol feeding**

Mouse	Diet	Fatty liver (0–4+)	Spotty necrosis (0–2+)	Submassive necrosis (0–2+)	Inflammation (0–2+)
WT	Ethanol	2.8 ± 0.7	0	0	0.5 ± 0.3
NS5A Tg	Ethanol	1.9 ± 0.6	0.5 ± 0.2	1.5 ± 0.4 <sup>†</sup>	1.4 ± 0.6 <sup>†</sup>
Tlr4 <sup>-/-</sup> NS5A Tg	Ethanol	1.0 ± 0.3 <sup>‡</sup>	0.1 ± 0.2	0.1 ± 0.1 <sup>†</sup>	0.2 ± 0.2 <sup>‡</sup>
NS5A Tg	Ethanol plus antibiotics	1.9 ± 0.3	0.3 ± 0.4	0.4 ± 0.1 <sup>†</sup>	0.3 ± 0.4 <sup>‡</sup>
NS5A Tg	Ethanol plus LPS	2.2 ± 0.5	1.8 ± 0.5	1.6 ± 0.2 <sup>‡</sup>	1.7 ± 0.7 <sup>‡</sup>

Fatty liver: 2+, 25≈50% hepatocytes with fat; 3+, 50≈75% with fat; 4+, >75% with fat. Submassive necrosis/inflammation: 1+, lesions encompassing less than one third acinus; 2+, lesions larger than whole acini.

<sup>†</sup>*P* < 0.05 compared with WT.

<sup>‡</sup>*P* < 0.05 compared with respective ethanol diet-fed NS5A Tg mice.



**Table S2. Disruption of *Tlr4* prevents tumor development in NS5A Tg mice fed the alcohol diet for 12 months**

Mouse	Diet	N	Tumor, %	Survival, %	Daily consumption, mL/mouse	Serum TNF- $\alpha$ , pg/mL	Body weight, g		Liver weight, g	Ratio of liver to body
							Begin	End		
WT	Control	22	0	86	17.2 $\pm$ 3.4	3 $\pm$ 1	23.8 $\pm$ 2.1	33.0 $\pm$ 2.1	1.3 $\pm$ 0.3	3.9
<i>Tlr4</i> <sup>-/-</sup>	Control	24	0	87	18.1 $\pm$ 3.1	4 $\pm$ 2	23.9 $\pm$ 2.2	33.5 $\pm$ 2.3	1.2 $\pm$ 0.2	3.7
NS5A Tg	Control	41	0	86	18.1 $\pm$ 4.1	4 $\pm$ 3	24.7 $\pm$ 2.6	34.1 $\pm$ 3.7	1.6 $\pm$ 0.3	4.5
<i>Tlr4</i> <sup>-/-</sup> NS5A Tg	Control	18	0	83	17.6 $\pm$ 3.6	3 $\pm$ 2	23.5 $\pm$ 1.7	35.9 $\pm$ 3.5	1.5 $\pm$ 0.4	3.9
WT	Ethanol	21	0	67	15.3 $\pm$ 2.8	12 $\pm$ 5 <sup>†</sup>	25.9 $\pm$ 2.8	31.2 $\pm$ 2.5	1.5 $\pm$ 0.5	5.2
<i>Tlr4</i> <sup>-/-</sup>	Ethanol	26	0	69	16.1 $\pm$ 4.4	7 $\pm$ 5	23.7 $\pm$ 2.4	29.2 $\pm$ 3.6	1.5 $\pm$ 0.7	3.9
NS5A Tg	Ethanol	42	23 <sup>‡</sup>	62	15.7 $\pm$ 3.0	24 $\pm$ 8 <sup>§</sup>	24.3 $\pm$ 3.3	29.5 $\pm$ 3.9	1.9 $\pm$ 0.8	6.7
<i>Tlr4</i> <sup>-/-</sup> NS5A Tg	Ethanol	19	0	63	16.3 $\pm$ 4.0	9 $\pm$ 6 <sup>¶</sup>	24.5 $\pm$ 2.7	30.2 $\pm$ 3.8	1.7 $\pm$ 0.5	5.4

The percentage of males and female animals in different experimental groups ranged 45–55% males and 45–53% females. The tumor incidences in the 2 sexes in ethanol-fed TLR4 Tg mice were 13% for females and 36% for males ( $P > 0.05$ ,  $\chi^2$  test).

<sup>†</sup> $P < 0.05$  compared with respective control diet-fed groups.

<sup>‡</sup> $P < 0.006$  compared with all other groups.

<sup>§</sup> $P < 0.05$  compared with ethanol-fed WT.

<sup>¶</sup> $P < 0.02$  compared with ethanol-fed *Tlr4*<sup>-/-</sup>NS5A.

**Table S3. Sex difference of tumor development in NS5A Tg mice fed the alcohol diet for 12 months**

Mouse	Diet	N	Tumor, %	Survival, %	Sex, n: M/F	Survived mice, n: M/F	Tumor-bearing mice, n (%): M/F
WT	Ethanol	21	0	68	21/20	15/13	0/0
NS5A Tg	Ethanol	42	23 <sup>†</sup>	62	19/23	11/15	4 (36)/2 (13) <sup>‡</sup>

<sup>†</sup> $P < 0.006$ , Student's  $t$  test was performed to calculate statistical significance in comparison to those of WT mice.

<sup>‡</sup> $P = 0.736$ ,  $\chi^2$  test was performed to compare incidence of tumor development in sex difference, showing no statistical sex difference.